UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 440

Sortiert nach

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies

International journal of molecular sciences, 2023-05, Vol.24 (10), p.8871

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Nature reviews. Clinical oncology, 2016-08, Vol.13 (8), p.516-524

2016

Link zum Volltext

Verfügbarkeit prüfen

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Frontiers in oncology, 2021-08, Vol.11, p.728018-728018

2021

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

Oral oncology, 2019-08, Vol.95, p.127-135

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical cancer research, 2020-08, Vol.26 (16), p.4268-4279

2020

Link zum Volltext

Verfügbarkeit prüfen

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

Molecular therapy. Oncolytics, 2021-12, Vol.23, p.266-276

2021

Link zum Volltext

Verfügbarkeit prüfen

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

Oncoimmunology, 2018-03, Vol.7 (3), p.e1395996

2018

Link zum Volltext

Verfügbarkeit prüfen

Natural Born Killers: NK Cells in Cancer Therapy

Cancers, 2020-07, Vol.12 (8), p.2131

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

Clinical cancer research, 2008-06, Vol.14 (11), p.3536-3544

2008

Link zum Volltext

Verfügbarkeit prüfen

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell–Mediated Killing

International journal of radiation oncology, biology, physics, 2016-05, Vol.95 (1), p.120-130

2016

Link zum Volltext

Verfügbarkeit prüfen

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Oncotarget, 2016-06, Vol.7 (23), p.33498-33511

2016

Link zum Volltext

Verfügbarkeit prüfen

Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses

Journal of translational medicine, 2024-05, Vol.22 (1), p.524-16, Article 524

2024

Link zum Volltext

Verfügbarkeit prüfen

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

eLife, 2020-07, Vol.9

2020

Link zum Volltext

Verfügbarkeit prüfen

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation

Frontiers in immunology, 2022-09, Vol.13, p.993624-993624

2022

Link zum Volltext

Verfügbarkeit prüfen

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

The Journal of experimental medicine, 2006-05, Vol.203 (5), p.1259-1271

2006

Link zum Volltext

Verfügbarkeit prüfen

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF

Proceedings of the National Academy of Sciences - PNAS, 2014-04, Vol.111 (17), p.E1749-E1758

2014

Link zum Volltext

Verfügbarkeit prüfen

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models

Oncoimmunology, 2022-12, Vol.11 (1), p.2124666-2124666

2022

Link zum Volltext

Verfügbarkeit prüfen

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

Clinical cancer research, 2008-05, Vol.14 (10), p.3060-3069

2008

Link zum Volltext

Verfügbarkeit prüfen

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Cells (Basel, Switzerland), 2022-11, Vol.11 (23), p.3826

2022

Link zum Volltext

Verfügbarkeit prüfen

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002258

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression

PloS one, 2013-07, Vol.8 (7), p.e70417-e70417

2013

Link zum Volltext

Verfügbarkeit prüfen

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

Frontiers in oncology, 2024-04, Vol.14, p.1376622-1376622

2024

Link zum Volltext

Verfügbarkeit prüfen

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies

Frontiers in oncology, 2022-10, Vol.12, p.1012058-1012058

2022

Link zum Volltext

Verfügbarkeit prüfen

Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy

Vaccines (Basel), 2021-05, Vol.9 (5), p.509

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(374)
Mit Volltextzugriff
(408)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(440)
Japanisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

Natural Born Killers: NK Cells in Cancer Therapy

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell–Mediated Killing

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies

Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy

Suchergebnisse filtern